Presentation: Better health for people, Brighter future for the world

Better health for people, Brighter future for the world

40th Annual J.P. Morgan Healthcare Conference

Christophe Weber

President & CEO

January 10th, 2022

Important Notice

For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this presentation or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this presentation may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

Financial Information and Certain Non-IFRS Financial Measures

Takeda's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

This presentation and materials distributed in connection with this presentation include certain financial measures not presented in accordance with International Financial Reporting Standards ("IFRS"), such as Underlying Revenue, Core Operating Profit, Underlying Core Operating Profit, Core Net Profit, Underlying Core EPS, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda's performance, core results and underlying trends. Takeda's non- IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as "reported" measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures, which are on slides 21-28.

Medical information

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

2

3

A Global, Values-based Biopharmaceutical Company

TOKYO	GREATER
BOSTON
Takeda
AREA
Global HQ
Global Hub

MANUFACTURING	RESEARCH
31SITES	3SITES

FY2020 GLOBAL REVENUE

13%
EMERGING
MARKETS	APPROX.
21%	29BN	49%
	U.S.
EUROPE &
CANADA	USD*
18%
JAPAN

5 KEY BUSINESS AREAS

(% OF FY2020 REVENUE)

18%

OTHER24%

GI

13% NEURO-

SCIENCE19% RARE

13%DISEASES

TOP EMPLOYER® IN

PR ESENCE: APPROX. IN

R&D INVESTMENT APPROX.

ONCOLOGY

13%

COUNTRIES	COUNTRIES &	BN PLANNED
& 4 REGIONS
80 REGIONS	$4.7 FOR FY21*
38 A S O F J A N U A R Y 2 0 2 1

PLASMA-DERIVED

THERAPIES

4

*Convenience translation of reported JPY figures into USD calculated at 110.6 JPY/USD

Executing to deliver topline acceleration, competitive margins & strong cash flow

UNDERLYING REVENUE GROWTH1

UNDERLYING CORE O.P. MARGIN1

Mid-single digit

• Accelerating topline growth with

+2.2%

30.2% ~30%

14 Global Brands and New

Product Launches

28.9%

FY2019	FY2020	FY2021	FY2019	FY2020	FY2021
		(guidance)			(guidance)

NET DEBT / ADJ. EBITDA2

4.7x

3.8x 3.2x

+2.2%

• Highly innovative pipeline to

support long-term growth outlook

• Competitive Underlying Core

Operating Profit1 margins

• Strong cash flow supporting

deleveraging, targeting "low 2s"

Net Debt / Adj. EBITDA2 by FY2023

• Well-established dividend policy

and announced first share

buyback program since 2008

Mar 2019

Mar 2020

Mar 2021

5 1. Please refer to slide 18 for definition, and 21-23 for reconciliation

2. Please refer to slide 20 for definition, and 24-28 for reconciliation